购物车
- 全部删除
- 您的购物车当前为空
Atopaxar (E5555) 是一种高效、可口服的,选择性的,可逆的凝血酶受体蛋白酶激活受体-1 (PAR-1) 拮抗剂。它是一种抗血小板剂,能干扰血小板信号,可用于动脉粥样硬化血栓性疾病的研究。
Atopaxar (E5555) 是一种高效、可口服的,选择性的,可逆的凝血酶受体蛋白酶激活受体-1 (PAR-1) 拮抗剂。它是一种抗血小板剂,能干扰血小板信号,可用于动脉粥样硬化血栓性疾病的研究。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 541 | 现货 | |
2 mg | ¥ 826 | 现货 | |
5 mg | ¥ 1,470 | 现货 | |
10 mg | ¥ 2,560 | 现货 | |
25 mg | ¥ 4,170 | 现货 | |
50 mg | ¥ 5,930 | 现货 | |
100 mg | ¥ 7,830 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,710 | 现货 |
产品描述 | Atopaxar (E5555), a reversible PAR-1 thrombin receptor antagonist, interferes with platelet signaling. Atopaxar has been investigated for the treatment of Coronary Artery Disease and Acute Coronary Syndrome. |
激酶实验 | Kinase assays: WHI-P154 is tested in kinase assays. The panel of kinases is selected to broadly cover the kinome, providing a good approximation of specificity. For all kinases, recombinant rat (IKKβ) or human (all others), full-length or GST-kinase domain fusion proteins, are used. WHI-P154 is inactive (concentration that inhibits response by 50% [IC50] > 30 μM) for the following kinases: AKT, AuroraA, cdk2, cdk6, CHK1, FGFR1, GSK3b, IKKb, IKKi, INSR, MAPK1, MAPKAP-K2, MASK, MET, PAK4, PDK1, PKCb, ROCK1, TaoK3, TrkA. |
别名 | 阿托帕沙, ER-172594-00, E5555 |
分子量 | 527.63 |
分子式 | C29H38FN3O5 |
CAS No. | 751475-53-3 |
Smiles | CCOc1cc2CN(CC(=O)c3cc(N4CCOCC4)c(OC)c(c3)C(C)(C)C)C(=N)c2c(F)c1OCC |
密度 | 1.22 g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 25 mg/mL (47.38 mM) ![]() | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
|
评论内容